New drugs for ovarian cancer

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 77-82

  Bell McGuinn, K ^a   Konner, J ^a   Tew, W ^a   Spriggs Dr , D R ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Angiogenesis; Antibodies; DNA repair; New drugs

Indexed keywords

ABAGOVOMAB; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CALICHEAMICIN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; INIPARIB; MAYTANSINE; MONOCLONAL ANTIBODY; NEW DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIRAPARIB; OLAPARIB; PACLITAXEL; PLACEBO; PLATINUM; TOPOTECAN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; APOPTOSIS; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84869233758     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr531     Document Type: Conference Paper

References (44)

1. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database System Rev 2006; CD005340.
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
4. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-1960.
5. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
6. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 2009; 361: 123-134.
7. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
8. Kaye S, Kaufman B, Lubinski J et al. Phase II stuy of the oral PARP inhibitor olaparib (AZD2281) vs liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann Oncol 2010; (Suppl 8): viii304-viii313 (Abstr 9710).
9. Ledermann JA, Harter P, Gourley C et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer. J Clin Oncol 2011; 15s (Suppl): Abstr 5003.
10. Sandhu SK, Wenham RM, Wilding G et al. First-in-human trial of a poly(ADPribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. In Proceedings of The American Society of Clinical Oncology. J Clin Oncol 2010; Abstr 3001. American Society of Clinical Oncology, Chicago, IL.
11. Penson RT, Whalen C, Lasonde B et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinumsensitive recurrent ovarian cancer. J Clin Oncol 2011; 15s (Suppl): Abstr 5004.
12. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
13. Ledermann JA, Gabra H, Jayson GC et al. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res 2010; 16: 4899-4905.
14. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
15. Ramakrishnan S, Subramanian IV, Yokoyama Y et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8: 169-182.
16. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1-7.
17. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121: 230-238.
18. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
19. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165-5171.
20. Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; 28: 18s, 2010 (suppl; abstr LBA1).
21. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Current Pharm Design 2007; 13: 2025-2044.
22. Beck E, Hofmann M, Bernhardt G et al. In vitro activity of immunoconjugates between cisplatin and an anti-CA125 monoclonal antibody on ovarian cancer cell lines. Cell Biophys 1994; 24-25: 163-173.
23. Chan SY, Gordon AN, Coleman RE et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003; 52: 243-248.
24. Pai LH, Bookman MA, Ozols RF et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991; 9: 2095-2103.
25. Trail PA, Willner D, Lasch SJ et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212-215.
26. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-169.
27. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26: 925-932.
28. Onda M, Nagata S, FitzGerald DJ et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177:8822-8834.
29. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
30. Perren T, Swart AM, Pfisterer J et al. ICON7-a phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010; 21 (Suppl 8): viii1-viii12 (LBA4).
31. Tew WP, Colombo N, Ray-Coquard I et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5508.
32. Karlan BY, Oza AM, Hansen VL et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010; 28 (Suppl): Abstr 5000.
33. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27:5601-5606.
34. Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011; 29: 69-75.
35. Biagi JJ, Oza AM, Chalchal HI et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 2011; 22: 335-340.
36. Friedlander M, Hancock KC, Rischin D et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-37.
37. Thompson DS, Patnaik A, Bendell JC et al. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 2010: 28 (15s):Abstr 3058.
38. Woll PJ, O'Brien M, Fossella F et al. Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. In ESMO, Milan, Italy, 2010. Ann Oncol 2010; 21 (Suppl 8): viii162-viii184 (Abstr 536p).
39. Emons G, Tomov S, Harter P et al. AGO Study Group. Phase II study of AEZS-108(AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptorpositive platinum resistant ovarian cancer. J Clin Oncol 2010; 28 (Suppl 15):Abstr 5035.
40. Hassan R, Kreitman R, Strauss L et al. S1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I and pharmacokinetic study of alternate-day infusion. In Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002. Abstract 113. American Society of Clinical Oncology, Alexandria, VA.
41. Cizeau J, Grenkow DM, Brown JG et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009; 32:574-584.
42. Jeffers ME, Pollack VA, Tse KF et al. CR014-vcMMAE, a potent fully human monoclonal antibody-monomethylauristatin E-conjugated drug targeting ovarian and renal cell carcinoma. In Proceedings of the American Association for Cancer Research, LaRochelle, 2006. Abstr 2324. American Association for Cancer Research, Philadelphia, PA.
43. Lee JW, Han HD, Shahzad MM et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009; 101: 1193-1205.
44. Ryan MC, Kostner H, Gordon KA et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN- 75. Br J Cancer 2010; 103: 676-684.